In keeping with the finding that serotonergic antagonists affect the activity of BTIC in mouse and human models of breast cancer, several studies have demonstrated that genetic inhibition of TPH1 or 5-HTRs have a wide range of consequences on tumor cell phenotypes [55,64]. The gene discussed is TPH1; the disease is breast carcinoma.